The group's principal activity is to develop licenses and markets biotech and therapeutic product lines. The group is a development stage company. The products of the group include erythrogentm and chondroitin sulfate. Erythrogentm is a cell culture additive, sold to research laboratories and pharmaceutical companies for incorporation into their experimental cell culture media. On 03-Oct- 2002 the group acquired element 21 golf company.
